LONGBOARD PHARMACEUTICALS IN
COM · Common Stock · CUSIP 54300N103
0
institutional holders
-127 vs Q3 2024
—reported value*
0 new
0 added
0 reduced
125 sold out
net sold ≈ $1.3bn (-39.9m shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable.
Trends to Q4 2024
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 20 |
| Q4 2022 | 19 |
| Q1 2023 | 26 |
| Q2 2023 | 51 |
| Q3 2023 | 52 |
| Q4 2023 | 53 |
| Q1 2024 | 107 |
| Q2 2024 | 102 |
| Q3 2024 | 127 |
| Q4 2024 | 0 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q1 2023 | 22 | 3 |
| Q2 2023 | 41 | 8 |
| Q3 2023 | 24 | 18 |
| Q4 2023 | 29 | 16 |
| Q1 2024 | 94 | 12 |
| Q2 2024 | 67 | 51 |
| Q3 2024 | 85 | 39 |
| Q4 2024 | 0 | 125 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
CallsPuts
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q1 2024 | $660.6k | $1.7m | 2.62 |
| Q2 2024 | $234.8k | $877.6k | 3.74 |
| Q3 2024 | $989.2k | $466.3k | 0.47 |
| Q4 2024 | $0 | $0 | — |
Biggest buyers
| None |
Biggest sellers
| FMR LLC | Sold out | -4.4m |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | Sold out | -3.2m |
| PRICE T ROWE ASSOCIATES INC /MD/ | Sold out | -2.9m |
| BlackRock, Inc. | Sold out | -2.8m |
| Cormorant Asset Management, LP | Sold out | -2.8m |
| VANGUARD GROUP INC | Sold out | -2.0m |
| VIKING GLOBAL INVESTORS LP | Sold out | -2.0m |
| WELLINGTON MANAGEMENT GROUP LLP | Sold out | -1.6m |
| Polar Capital Holdings Plc | Sold out | -1.1m |
| Integral Health Asset Management, LLC | Sold out | -1.1m |
Holders, Q4 2024
| Manager | Shares | Change |
|---|